Protease activated receptors in cardiovascular function and disease

Molecular and Cellular Biochemistry

Volumn 263, Issue 1, 2004, Pages 227-239

  Barnes, Junor A ^a   Singh, Shamjeet ^a   Gomes, Aldrin V ^b  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Protease activated receptor; Thrombin

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; MEMBRANE PROTEIN; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; RECEPTOR SUBTYPE; SERINE PROTEINASE; THROMBIN; TRYPSIN; TRYPTASE;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; APOPTOSIS; ARTICLE; BINDING SITE; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; HEART MUSCLE CELL; HUMAN; LIGAND BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; CATHEPSINS; HUMANS; MODELS, CARDIOVASCULAR; MYOCYTES, CARDIAC; RECEPTORS, PROTEINASE-ACTIVATED; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

ANIMALIA; MUS MUSCULUS; RICKETTSIA SP. PAR;

EID: 4544377101     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000041864.14092.5b     Document Type: Article

References (131)

1. Vu TK, Hung DT, Wheaton VI, Coughlin SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057-1068, 1991
2. Cocks TM, Moffatt JD: Protease-activated receptors: sentries for inflammation? Trends Pharmacol Sci 21: 103-108, 2000
3. Dery O, Corvera CU, Steinhoff M, Bunnett NW: Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 274: C1429-CI452, 1998
4. Sabri A, Muske G, Zhang H, Pak E, Darrow A, Andrade-Gordon P, Steinberg SF: Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res 86: 1054-1061, 2000
5. Patella V, Marino I, Arbustini E, Lamparter-Schummert B, Verga L, Adt M, Marone G: Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 97: 971-978, 1998
6. Kovanen PT, Kaartinen M, Paavonen T: Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92: 1084-1088, 1995
7. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV, Tam C, Coughlin SR: A dual thrombin receptor system for platelet activation. Nature 394: 690-694, 1998
8. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC: Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 95: 6642-6646, 1998
9. Pierce KL, Premont RT, Lefkowitz RJ: Seven-Transmembrane receptors. Nature Rev 3: 639-650, 2002
10. Rockman HA, Koch WJ, Lefkowitz RJ: Seven-transmembrane-spanning receptors and heart function. Nature 415: 206-212, 2002
11. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J: Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 91: 9208-9212, 1994
12. Kawabata A, Kuroda R: Protease-activated receptor (PAR), a novel family of G protein-coupled seven trans-membrane domain receptors: activation mechanisms and physiological roles. Jpn J Pharmacol 82: 171-174, 2000
13. Coughlin SR, Camerer E: Participation in inflammation. J Clin Invest 111: 25-27, 2003
14. Mackie EJ, Pagel CN, Smith R, de Niese MR, Song SJ, Pike RN: Protease-activated receptors: a means of converting extracellular proteolysis into intracellular signals. IUBMB Life 53: 277-281, 2002
15. Connolly AJ, Ishihara H, Kahn ML, Farese RV, Coughlin SR: Role of the thrombin receptor in development and evidence for a second receptor. Nature 381: 516-519, 1996
16. Hollenberg MD: Protease-activated receptors: PAR4 and counting: How long is the course? Trends Pharmacol Sci 20: 271-273, 1999
17. Connolly AJ, Suh DY, Hunt TK, Coughlin SR: Mice lacking the thrombin receptor, PAR1, have normal skin wound healing. Am J Pathol 151: 1199-1204, 1997
18. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR: Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386: 502-506, 1997
19. Sabri A, Alcott SG, Elouardighi H, Pak E, Derian C, Andrade-Gordon P, Kinnally K, Steinberg SF: Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. J Biol Chem 278: 23944-23954, 2003
20. Kahn ML, Hammes SR, Botka C, Coughlin SR: Gene and locus structure and chromosomal localization of the protease-activated receptor gene family. J Biol Chem 273: 23290-23296, 1998
21. Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, Kahn M, Nelken NA, Coughlin SR, Payan DG, Bunnett NW: Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 314(Pt 3): 1009-1016, 1996
22. Coughlin SR: Thrombin signaling and protease-activated receptors. Nature 407: 258-264, 2000
23. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR: Protection against thrombosis in mice lacking PAR3. Blood 100: 3240-3244, 2002
24. Cook JJ, Sitko GR, Bednar B, Condra C, Mellott MJ, Feng DM, Nutt RF, Shafer JA, Gould RJ, Connolly TM: An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 91: 2961-2971, 1995
25. Coughlin SR: How the protease thrombin talks to cells. Proc Natl Acad Sci USA 96: 11023-11027, 1999
26. Vergnolle N, Hollenberg MD, Wallace JL: Pro- and anti-inflammatory actions of thrombin: A distinct role for proteinase-activated receptor-1 (PAR1). Br J Pharmacol 126: 1262-1268, 1999
27. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maraganore JM, Stone SR: Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med 183: 821-827, 1996
28. Kawabata A, Kuroda R, Nishikawa H, Asai T, Kataoka K, Taneda M: Enhancement of vascular permeability by specific activation of protease-activated receptor-1 in rat hindpaw: A protective role of endogenous and exogenous nitric oxide. Br J Pharmacol 126: 1856-1862, 1999
29. de Garavilla L, Vergnolle N, Young SH, Ennes H, Steinhoff M, Ossovskaya VS, D'Andrea MR, Mayer EA, Wallace JL, Hollenberg MD, Andrade-Gordon P, Bunnett NW: Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br J Pharmacol 133: 975-987, 2001
30. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar-Shavit R: Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4: 909-914, 1998
31. Mohle R, Green D, Moore MA, Nachman RL, Rafii S: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94: 663-668, 1997
32. Vaughan PJ, Pike CJ, Cotman CW, Cunningham DD: Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J Neurosci 15: 5389-5401, 1995
33. Kawabata A, Kuroda R, Minami T, Kataoka K, Taneda M: Increased vascular permeability by a specific agonist of protease-activated receptor-2 in rat hindpaw. Br J Pharmacol 125: 419-422, 1998
34. Vergnolle N: Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo. J Immunol 163: 5064-5069, 1999
35. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, Mitchell SE, Williams LM, Geppetti P, Mayer EA, Bunnett NW: Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 6: 151-158, 2000
36. Cocks TM, Fong B, Chow JM, Anderson GP, Frauman AG, Goldie RG, Henry PJ, Carr MJ, Hamilton JR, Moffatt JD: A protective role for protease-activated receptors in the airways. Nature 398: 156-160, 1999
37. Napoli C, Cicala C, Wallace JL, de Nigris F, Santagada V, Caliendo G, Franconi F, Ignarro LJ, Cirino G: Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc Natl Acad Sci USA 97: 3678-3683, 2000
38. Kawabata A, Kinoshita M, Nishikawa H, Kuroda R, Nishida M, Araki H, Arizono N, Oda Y, Kakehi K: The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. J Clin Invest 107: 1443-1450, 2001
39. Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, Hollenberg MD, Wallace JL, Morelli A, Cirino G: Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci USA 98: 13936-13941, 2001
40. Milia AF, Salis MB, Stacca T, Pinna A, Madeddu P, Trevisani M, Geppetti P, Emanueli C: Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. Circ Res 91: 346-352, 2002
41. Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, Cirino G, Gerard N, Basbaum AI, Andrade-Gordon P, Hollenberg MD, Wallace JL: Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. Nat Med 7: 821-826, 2001
42. Kawabata A: PAR2: structure, function and relevance to human disease of the gastric mucosa. Expert Reviews in Molecular Medicine (http://www.expertreviews.org/) 2002
43. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD: Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 22: 146-152, 2001
44. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR: Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103: 879-887, 1999
45. Nakanishitsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR: PAR3 is a colactor for PAR4 activation by thrombin. Nature 404: 609-613, 2000
46. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR: Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413: 74-78, 2001
47. Kawabata A, Saifeddine M, Al-Ani B, Leblond L, Hollenberg MD: Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: Activation of PAR2 by PAR1-targeted ligands. J Pharmacol Exp Ther 288: 358-370, 1999
48. Hollenberg MD, Saifeddine M, Al-Ani B, Kawabata A: Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides. Can J Physiol Pharmacol 75: 832-841, 1997
49. Andraderdon P, Maryanoff BE, Derian CK, Zhang HC, Addo MF, Darrow AL, Eckardt AJ, Hoekstra WJ, McComsey DF, Oksenberg D, Reynolds EE, Santulli RJ, Scarborough RM, Smith CE, White KB: Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA 96: 12257-12262, 1999
50. Kato Y, Kita Y, Nishio M, Hirasawa Y, Ito K, Yamanaka T, Motoyama Y, Seki J: In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol 384: 197-202, 1999
51. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR: Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem 272: 5783-5791, 1997
52. Sugden PH: Signaling in myocardial hypertrophy: Life after calcineurin? Circ Res 84: 633-646, 1999
53. Al-Ani B, Saifeddine M, Kawabata A, Renaux B, Mokashi S, Hollenberg MD: Proteinase-activated receptor 2 (PAR(2)): Development of a ligand-binding assay correlating with activation of PAR(2) by PAR(1)- and PAR(2)-derived peptide ligands. J Pharmacol Exp Ther 290: 753-760, 1999
54. Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, Cattaneo M, Kunapuli SP: Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 99: 3629-3636, 2002
55. Hollenberg MD, Saifeddine M, Al-Ani B, Gui Y: Proteinase-activated receptor 4 (PAR4): Action of PAR4-activating peptides in vascular and gastric tissue and lack of cross-reactivity with PAR1 and PAR2. Can J Physiol Pharmacol 77: 458-464, 1999
56. Hollenberg MD, Saifeddine M: Proteinase-activated receptor 4 (PAR4): Activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can J Physiol Pharmacol 79: 439-442, 2001
57. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW: Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 96: 11189-11193, 1999
58. Faruqi TR, Weiss EJ, Shapiro MJ, Huang W, Coughlin SR: Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem 275: 19728-19734, 2000
59. Andrade Gordon P, Derian CK, Maryanoff BE, Zhang HC, Addo MF, Cheung WM, Damiano BP, D'Andrea MR, Darrow AL, de Garavilla L, Eckardt AJ, Giardino EC, Haertlein BJ, McComsey DF: Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 298: 34-42, 2001
60. Nishikawa H, Kawabata A, Kawai K, Kuroda R: Guinea pig platelets do not respond to GYPGKF, a protease-activated receptor-4-activating peptide: A property distinct from human platelets. Blood Coagul Fibrinolysis 11: 111-113, 2000
61. Hung DT, Wong YH, Vu TK, Coughlin SR: The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. J Biol Chem 267: 20831-20834, 1992
62. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R: Proteinase-activated receptors. Pharmacol Rev 53: 245-282, 2001
63. Steinberg SF, Robinson RB, Lieberman HB, Stern DM, Rosen MR: Thrombin modulates phosphoinositide metabolism, cytosolic calcium, and impulse initiation in the heart. Circ Res 68: 1216-1229, 1991
64. Jiang T, Kuznetsov V, Pak E, Zhang H, Robinson RB, Steinberg SF: Thrombin receptor actions in neonatal rat ventricular myocytes. Circ Res 78: 553-563, 1996
65. Lerner DJ, Chen M, Tram T, Coughlin SR: Agonist recognition by proteinase-activated receptor 2 and thrombin receptor. Importance of extracellular loop interactions for receptor function. J Biol Chem 271: 13943-13947, 1996
66. Boluyt MO, Zheng JS, Younes A, Long X, O'Neill L, Silverman H, Lakatta EG, Crow MT: Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. Circ Res 81: 176-186, 1997
67. Drexler H: Nitric oxide synthases in the failing human heart: A doubled-edged sword? Circulation 99: 2972-2975, 1999
68. Covic L, Gresser AL, Kuliopulos A: Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 39: 5458-5467, 2000
69. 2+ signaling. Eur J Biochem 249: 547-555, 1997
70. Lau LF, Pumiglia K, Cote YP, Feinstein MB: Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators. Biochem J 303(Pt 2): 391-400, 1994
71. Lasne D, Donato J, Falet H, Rendu F: Different abilities of thrombin receptor activating peptide and thrombin to induce platelet calcium rise and full release reaction. Thromb Haemost 74: 1323-1328, 1995
72. i movements in platelets stimulated by thrombin and TRAP: The involvement of alpha(IIb)beta3-mediated TXA2 synthesis. Thromb Haemost 79: 1184-1190, 1998
73. Hammes SR, Coughlin SR: Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: Evidence for a novel mechanism for preventing or terminating signaling by PAR1's tethered ligand. Biochemistry 38: 2486-2493, 1999
74. Kuliopulos A, Nelson NP, Yamada M, Walsh CT, Furie B, Furie BC, Roth DA: Localization of the affinity peptide-substrate inactivator site on recombinant vitamin K-dependent carboxylase. J Biol Chem 269: 21364-21370, 1994
75. 2+. Biochem J 258: 923-926, 1989
76. 2+ influx. Biochemistry 37: 9776-9783, 1998
77. Banfic H, Downes CP, Rittenhouse SE: Biphasic activation of PKB alpha/Akt in platelets. Evidence for stimulation both by phosphatidylinositol 3,4-bisphosphate, produced via a novel pathway, and by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 11630-11637, 1998
78. Kinlough-Rathbone RL, Perry DW, Guccione MA, Rand ML, Packham MA: Degranulation of human platelets by the thrombin receptor peptide SFLLRN: Comparison with degranulation by thrombin. Thromb Haemost 70: 1019-1023, 1993
79. Kinlough-Rathbone RL, Perry DW, Packham MA: Contrasting effects of thrombin and the thrombin receptor peptide, SFLLRN, on aggregation and release of 14C-serotonin by human platelets pretreated with chymotrypsin or serratia marcescens protease. Thromb Haemost 73: 122-125, 1995
80. Mazzucato M, Marco LD, Masotti A, Pradella P, Bahou WF, Ruggeri ZM: Characterization of the initial alpha-thrombin interaction with glycoprotein Ib alpha in relation to platelet activation. J Biol Chem 273: 1880-1887, 1998
81. Yang X, Sun L, Ghosh S, Rao AK: Human platelet signaling defect characterized by impaired production of inositol-1,4,5-triphosphate and phosphatidic acid and diminished Pleckstrin phosphorylation: Evidence for defective phospholipase C activation. Blood 88: 1676-1683, 1996
82. Offermanns S, Toombs CF, Hu YH, Simon MI: Defective platelet activation in G alpha(q)-deficient mice. Nature 389: 183-186, 1997
83. Gabbeta J, Yang X, Kowalska MA, Sun L, Dhanasekaran N, Rao AK: Platelet signal transduction defect with G alpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses. Proc Natl Acad Sci USA 94: 8750-8755, 1997
84. Clark EA, Brugge JS: Integrins and signal transduction pathways: The road taken. Science 268: 233-239, 1995
85. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR: Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 401: 808-811, 1999
86. Lind SE, Janmey PA, Chaponnier C, Herbert TJ, Stossel TP: Reversible binding of actin to gelsolin and profilin in human platelet extracts. J Cell Biol 105: 833-842, 1987
87. Shattil SJ, Ginsberg MH, Brugge JS: Adhesive signaling in platelets. Curr Opin Cell Biol 6: 695-704, 1994
88. Kovacsovics TJ, Hartwig JH: Thrombin-induced GPIb-IX centralization on the platelet surface requires actin assembly and myosin II activation. Blood 87: 618-629, 1996
89. Molino M, Blanchard N, Belmonte E, Tarver AP, Abrams C, Hoxie JA, Cerletti C, Brass LF: Proteolysis of the human platelet and endothelial cell thrombin receptor by neutrophil-derived cathepsin G. J Biol Chem 270: 11168-11175, 1995
90. Parry MA, Myles T, Tschopp J, Stone SR: Cleavage of the thrombin receptor: Identification of potential activators and inactivators. Biochem J 320(Pt 1): 335-341, 1996
91. Si-Tahar M, Renesto P, Falet H, Rendu F, Chignard M: The phospholipase C/protein kinase C pathway is involved in cathepsin G-induced human platelet activation: Comparison with thrombin. Biochem J 313 (Pt 2): 401-408, 1996
92. Weksler BB, Jaffe EA, Brower MS, Cole OF: Human leukocyte cathepsin G and elastase specifically suppress thrombin-induced prostacyclin production in human endothelial cells. Blood 74: 1627-1634, 1989
93. Cumashi A, Ansuini H, Celli N, Deasi A, Oien PJ, Brass LF, Molino M: Neutrophil proteases can inactivate human PAR3 and abolish the co-receptor function of PAR3 on murine platelets. Thromb Haemost 85: 533-538, 2001
94. Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG, Mignatti P: Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase3: A role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 189: 197-206, 2001
95. Levkau B, Herren B, Koyama H, Ross R, Raines EW: Caspase-mediated cleavage of focal adhesion kinase pp125FAK and disassembly of focal adhesions in human endothelial cell apoptosis. J Exp Med 187: 579-586, 1998
96. Rokudai S, Fujita N, Hashimoto Y, Tsuruo T: Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis. J Cell Physiol 182: 290-296, 2000
97. Bachelder RE, Ribick MJ, Marchetti A, Falcioni R, Soddu S, Davis KR, Mercurio AM: p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell Biol 147: 1063-1072, 1999
98. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ: Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 99: 6252-6256, 2002
99. Saifeddine M, Al-Ani B, Cheng CH, Wang L, Hollenberg MD: Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. Br J Pharmacol 118: 521-530, 1996
100. Al-Ani B, Saifeddine M, Hollenberg MD: Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle. Can J Physiol Pharmacol 73: 1203-1207, 1995
101. Hollenberg MD, Saifeddine M, Al-Ani B: Proteinase-activated receptor-2 in rat aorta: Structural requirements for agonist activity of receptor-activating peptides. Mol Pharmacol 49: 229-233, 1996
102. Laniyonu AA, Hollenberg MD: Vascular actions of thrombin receptor-derived polypeptides: Structure-activity profiles for contractile and relaxant effects in rat aorta. Br J Pharmacol 114: 1680-1686, 1995
103. Hamilton JR, Cocks TM: Heterogeneous mechanisms of endothelium-dependent relaxation for thrombin and peptide activators of protease-activated receptor-1 in porcine isolated coronary artery. Br J Pharmacol 130: 181-188, 2000
104. Nakayama T, Hirano K, Nishimura J, Takahashi S, Kanaide H: Mechanism of trypsin-induced endothelium-dependent vasorelaxation in the porcine coronary artery. Br J Pharmacol 134: 815-826, 2001
105. McGuire JJ, Hollenberg MD, Andrade-Gordon P, Triggle CR: Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles. Br J Pharmacol 135: 155-169, 2002
106. Damiano BP, Cheung WM, Santulli RJ, Fung-Leung WP, Ngo K, Ye RD, Darrow AL, Derian CK, deravilla L, Andrade-Gordon P: Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther 288: 671-678, 1999
107. Cicala C, Pinto A, Bucci M, Sorrentino R, Walker B, Harriot P, Cruchley A, Kapas S, Howells GL, Cirino G: Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. Circulation 99: 2590-2597, 1999
108. Cicala C, Morello S, Santagada V, Caliendo G, Sorrentino L, Cirino G: Pharmacological dissection of vascular effects caused by activation of protease-activated receptors 1 and 2 in anesthetized rats. FASEB J 15: 1433-1435, 2001
109. Cicala C: Protease activated receptor 2 and the cardiovascular system. Br J Pharmacol 135: 14-20, 2002
110. Camerer E, Huang W, Coughlin SR: Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 97: 5255-5260, 2000
111. Kawabata A, Kuroda R, Nakaya Y, Kawai K, Nishikawa H, Kawao N: Factor Xa-evoked relaxation in rat aorta: Involvement of PAR-2. Biochem Biophys Res Commun 282: 432-435, 2001
112. Cheung WM, D'Andrea MR, Andrade-Gordon P, Damiano BP: Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler Thromb Vasc Biol 19: 3014-3024, 1999
113. Chaikof EL, Caban R, Yan CN, Rao GN, Runge MS: Growth-related responses in arterial smooth muscle cells are arrested by thrombin receptor antisense sequences. J Biol Chem 270: 7431-7436, 1995
114. D'Andrea MR, Derian CK, Leturcq D, Baker SM, Brunmark A, Ling P, Darrow AL, Santulli RJ, Brass LF, Andrade-Gordon P: Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. The Journal of Histochentistry and Cytochemistry: Official Journal of the Histochemistry Society 46: 157-164, 1998
115. Bono F, Lamarche I, Herbert JM: Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2 (PAR-2). Biochem Biophys Res Commun 241: 762-764, 1997
116. Molino M, Raghunath PN, Kuo A, Ahuja M, Hoxie JA, Brass LF, Barnathan ES: Differential expression of functional protease-activated receptor-2 (PAR-2) in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 18: 825-832, 1998
117. http://us.expasy.org
118. Vassallo RR, Kieber-Emmons T, Cichowski K, Brass LF: Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem 267: 6081-6085, 1992
119. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW: The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 249: 277-280, 1990
120. Barr AJ, Brass LF, Manning DR: Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells. A direct evaluation of selectivity in receptor. G protein coupling. J Biol Chem 272: 2223-2229, 1997
121. Camerer E, Kataoka H, Kahn M, Lease K, Coughlin SR: Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem 277: 16081-16087, 2002
122. Koshikawa N, Nagashima Y, Miyagi Y, Mizushima, H, Yanoma S, Yasumitsu H, Miyazaki K: Expression of trypsin in vascular endothelial cells. FEBS Lett 409: 442-448, 1997
123. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Woolkalis M, Brass LF: Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 272: 4043-4049, 1997
124. Fox MT, Harriott P, Walker B, Stone SR: Identification of potential activators of proteinase-activated receptor-2. FEBS Lett 417: 267-269, 1997
125. Selak MA, Chignard M, Smith JB: Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J 251: 293-299, 1988
126. Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent GJ: Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem 275: 35584-35591, 2000
127. Chambers RC, Dabbagh K, McAnulty RJ, Gray AJ, Blanc-Brude OP, Laurent GJ: Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem J 333(Pt 1): 121-127, 1998
128. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL: Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol 127: 1083-1090, 1999
129. Hwa JJ, Ghibaudi L, Williams P, Chintala M, Zhang R, Chatterjee M, Sybertz E: Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. Circ Res 78: 581-588, 1996
130. Vergnolle N: Review article: Proteinase-activated receptors-novel signals for gastrointestinal pathophysiology. Aliment Pharmacol Ther 14: 257-266, 2000
131. Sabri A, Guo J, Elouardighi H, Darrow AL, Andrade-Gordon P, Steinberg SF: Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase. J Biol Chem 278: 11714-11720, 2003